Literature DB >> 2523924

Is booster injection with hepatitis B vaccine necessary in healthy responders? A study of the immune response.

P J Wismans1, J van Hattum, G C Mudde, H J Endeman, J Poel, G C de Gast.   

Abstract

Loss of protective anti-HBs levels (less than 10 IU/l) was noted in 5 (13%) of 38 well documented healthy responders to hepatitis B vaccine 30 months after completing the initial standard vaccination series. Revaccination with a single booster injection of 20 micrograms hepatitis B vaccine intramuscularly resulted in anti-HBs levels well above those initially obtained, thus confirming considerable immunological memory. Both decline prior to and rise after booster injection were proportional to the anti-HBs level obtained initially. The antibody production after a single booster injection was closely monitored in 13 individuals. A swift response was observed from day 4 onwards in all subjects. Based on passive immunization data and in vitro infection of human hepatocytes, this time delay is likely to permit infection of hepatocytes. Therefore, until further data on longterm follow-up of vaccinated in individuals in whom anti-HBs levels have dropped to less than 10 IU/l reveal compelling evidence to the contrary, booster injections remain mandatory for those individuals at risk.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2523924     DOI: 10.1016/0168-8278(89)90013-5

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  12 in total

1.  Long-term persistence of T cell memory to HBsAg after hepatitis B vaccination.

Authors:  Ru-Xiang Wang; Greet J Boland; Jan van Hattum; Gijsbert C de Gast
Journal:  World J Gastroenterol       Date:  2004-01-15       Impact factor: 5.742

Review 2.  Strategies for hepatitis B immunisation.

Authors:  A P Catterall; I M Murray-Lyon
Journal:  Gut       Date:  1992-05       Impact factor: 23.059

Review 3.  Hepatitis B vaccine in celiac disease: yesterday, today and tomorrow.

Authors:  Giovanna Vitaliti; Andrea Domenico Praticò; Carla Cimino; Giovanna Di Dio; Elena Lionetti; Mario La Rosa; Salvatore Leonardi
Journal:  World J Gastroenterol       Date:  2013-02-14       Impact factor: 5.742

4.  The spot-ELISA: a sensitive in vitro method to study the immune response to hepatitis B surface antigen.

Authors:  P J Wismans; J van Hattum; G C De Gast; H J Endeman; J Poel; B Stolk; T Maikoe; G C Mudde
Journal:  Clin Exp Immunol       Date:  1989-10       Impact factor: 4.330

5.  Four-year experience with a recombinant hepatitis B vaccine.

Authors:  W Jilg; M Schmidt; F Deinhardt
Journal:  Infection       Date:  1989 Mar-Apr       Impact factor: 3.553

6.  A mathematical model predicting anti-hepatitis B virus surface antigen (HBs) decay after vaccination against hepatitis B.

Authors:  M C Honorati; A Palareti; P Dolzani; C A Busachi; R Rizzoli; A Facchini
Journal:  Clin Exp Immunol       Date:  1999-04       Impact factor: 4.330

7.  Strategies for hepatitis B infection.

Authors:  P J Wismans; J van Hattum
Journal:  Gut       Date:  1993-04       Impact factor: 23.059

Review 8.  Traditional management of liver disorders.

Authors:  M Messner; P Brissot
Journal:  Drugs       Date:  1990       Impact factor: 9.546

9.  Is a low dose of hepatitis B vaccine enough for a rapid vaccination scheme?

Authors:  Ru-Xiang Wang; Greet Boland; Ying Guo; Shao-Ping Lei; Chang-Hong Yang; Juan Chen; Jie Tian; Jin-Ying Wen; Ke-Hong Du; Jan van Hattum; Gijsbert C de Gast
Journal:  World J Gastroenterol       Date:  2003-10       Impact factor: 5.742

Review 10.  Strategies to increase responsiveness to hepatitis B vaccination in adults with HIV-1.

Authors:  Jennifer A Whitaker; Nadine G Rouphael; Srilatha Edupuganti; Lilin Lai; Mark J Mulligan
Journal:  Lancet Infect Dis       Date:  2012-12       Impact factor: 25.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.